生物仿制药
生物制药
指南
医学
业务
营销
生物技术
病理
内科学
生物
作者
Bikash Ranjan Meher,Sakthi Balan,Rashmi Ranjan Mohanty,Monalisa Jena,Smita Das
标识
DOI:10.4103/jpbs.jpbs_167_18
摘要
Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics.
科研通智能强力驱动
Strongly Powered by AbleSci AI